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Oxidative Stress in Kidney Transplantation:
Malondialdehyde Is an Early Predictive Marker of
Graft Dysfunction
Isabel Fonseca,1,2,3,6 Henrique Reguengo,4 Manuela Almeida,1,2 Leonı´dio Dias,1 La Salete Martins,1,2
Sofia Pedroso,1 Josefina Santos,1,2 Luı´sa Lobato,1,2 Anto´nio Castro Henriques,1,2 and Denisa Mendonc¸a3,5
Background. Oxidative stress is one of the most important components of the ischemia-reperfusion process after
kidney transplantation (KTx) and increases with graft dysfunction.
Methods. This prospective study was conducted on 40 consecutive KTx recipients to evaluate time-dependent
changes in oxidative stress-related parameters within the first week after KTx and to assess their performance in
predicting delayed graft function (DGF=dialysis requirement during initial posttransplant week) and graft function at
1 year. Blood samples were collected before (day 0) and after KTx (days 1, 2, 4, and 7). Total antioxidant capacity,
plasma levels of malondialdehyde (MDA), and activities of glutathione peroxidase, glutathione reductase and su-
peroxide dismutase were measured. Multivariable linear mixed and linear regression models, receiver-operating
characteristic (ROC), and areas under ROC curves (AUC-ROC) were used.
Results. At all time points after KTx, mean MDA levels were significantly higher in patients developing DGF (n=18).
Shortly after KTx (8Y12 hr), MDA values were higher in DGF recipients (on average, +0.16 Kmol/L) and increased
further on following day, contrasting with prompt functioning recipients. Day 1 MDA levels accurately predicted DGF
(AUC-ROC=0.90), with a performance higher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-
ROC=0.91). Multivariable analysis revealed that MDA levels on day 7 represented an independent predictor of 1-year
graft function. Antioxidant enzyme activities were not significantly changed during the study period and were not
predictors of 1-year graft function.
Conclusions. Increased MDA levels on day 1 after KTx might be an early prognostic indicator of DGF, and levels on
day 7 might represent a useful predictor of 1-year graft function.
Keywords: Oxidative stress, Malondialdehyde, Kidney transplantation, Kidney graft dysfunction.
(Transplantation 2014;97: 1058Y1065)
Ischemia-reperfusion (I/R) injury is a complex phenome-non in kidney transplantation (KTx) that can cause graft
dysfunction and determine both the early and long-term
outcomes of transplant recipients. Oxidative stress is one
of the most important components of I/R process (1Y3).
Reactive oxygen species (ROS) are products of normal cel-
lular metabolism that are completely inactivated by antiox-
idant defense mechanisms during physiological conditions.
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The antioxidant defense system can be predominantly divided
into endogenous enzymes, such as superoxide dismutases
(SOD), catalases, glutathione reductases (GR) and peroxi-
dases (GPx), and exogenous small molecules, such as carot-
enoids and vitamins A, C, and E (4). In some pathologic
conditions, an imbalance between ROS generation and anti-
oxidant capacity can result in enhanced ROS activity and
oxidative stress (5).
Markers of oxidative stress, including elevated levels of
malondialdehyde (MDA) and reduced antioxidant activity,
TABLE 1. Summary of baseline and clinical characteristics in kidney transplant donors and recipients (total sample and
categorized by delayed or prompt graft function)
Total (n=40) DGF (n=18) Non-DGF (n=22) P
Donor
Age (yr) 51.2T11.4 51.1T13.4 51.2T9.9 0.172
Male sex 26 (65) 14 (78) 12 (54.5) 0.125
Living donor 11 (27.5) 3 (16.7) 8 (36.4) 0.165
Expanded criteria donors 3 (7.5) 1 (5.6) 2 (9.1) 0.541
Serum creatinine (mg/dL) 0.81T0.18 0.85T0.21 0.78T0.16 0.318
Donor-recipient
HLA mismatches 3.39T1.24 3.38T1.07 3.41T1.46 0.941
Cold ischemia time (hr) 12.1T7.9 15.2T7.8 9.6T7.3 0.035*
Living donor 2.8T0.5 2.5T0.5 3.0T0.5 0.204
Deceased donor 16.2T5.9 18.1T5.1 14.1T6.2 0.088
Recipient
Age (yr) 49.2T15.2 56.3T10.9 43.3T15.9 0.006*
Male sex 26 (65) 11 (61) 15 (68) 0.641
White 40 (100) 18 (100) 22 (100) V
BMI (kg/m2) 24.8T4.9 26.2T4.4 23.6T5.0 0.091
Previous transplant 2 (5) 0 (0) 2 (9.1)
Time on dialysis (yr) 4.4T4.7 5.6T6.2 3.4T2.3 0.135
Pretransplant therapy
Dialysis 38 (95) 18 (100) 20 (90.9) 0.296
Preemptive transplantation 2 (5) 0 (0) 2 (9.1)
Cause of kidney disease
IgA nephropathy 7 (17.5) 2 (11.1) 5 (22.7) V
Glomerulonephritis 6 (15.0) 4 (22.2) 2 (9.1) V
Diabetic nephropathy 5 (12.5) 3 (16.7) 2 (9.1) V
Autosomal dominant polycystic kidney disease 3 (7.5) 3 (16.7) 0 (0) V
Unknown 4 (10.0) 1 (5.6) 3 (13.6) V
Others 15 (37.5) 5 (27.8) 10 (45.5) V
Peak PRA (%) 5.5 T 15.1 5.0 T 15.0 5.9 T 15.5 0.853
0 29 (72.5) 14 (77.8) 15 (68.2) V
1Y25 8 (20.0) 3 (16.7) 5 (22.7) V
26Y75 3 (7.5) 1 (5.6) 2 (9.0) V
Current PRA (%) 2.3 T 8.6 3.1 T 11.7 1.6 T 4.9 0.585
0 34 (85) 15 (83.3) 19 (86.4) V
1Y25 5 (12.5) 2 (11.1) 3 (13.6) V
26Y50 1 (2.5) 1 (5.6) 0 (0) V
Induction regimen
Antithymocyte globulin (ATG-F) 4 (10) 1 (5.6) 3 (13.6) 0.613
Basiliximab/Daclizumab 30 (75) 14 (77.8) 16 (72.7) 0.789
Immunosuppression at time of discharge
Steroids 38 (95.0) 18 (100) 20 (90.9) 0.296
Tacrolimus 38 (95.0) 17 (94.4) 21 (95.5) 0.886
Cyclosporine A 2 (0.05) 1 (5.6) 1 (5.6) 0.884
Values are expressed as meanTstandard deviation or absolute numbers and percentages. Comparisons between groups of continuous variables were done
using parametric (t test) or nonparametric (Mann-Whitney) tests; associations between categorical variables were analyzed using the W2 test and Fisher’s exact
test as appropriate; *PG0.05.
HLA, human leukocyte antigen; BMI, body mass index; PRA, panel reactive antibody.
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have been reported in renal patients (6Y9). The restoration
of kidney function after KTx can improve oxidative stress
(10), but certain studies (11, 12) have reported increased
systemic biomarkers of oxidative stress in KTx recipients,
particularly in the early phase (13, 14) and thereafter, coin-
ciding with chronic allograft dysfunction (11, 15Y18). De-
spite a significant amount of literature on oxidative stress
and renal disease, data regarding KTx in the early stages re-
main limited. Therefore, we investigated the time-dependent
changes in the antioxidant defense system during the first
week after transplantation by measuring the overall antioxi-
dant status (TAS) and the activity of the predominant anti-
oxidant enzymes as a response to lipid peroxidation evaluated
by MDA levels.
The purposes of this study were as follows:
to assess whether oxidative markers differ between patients
(pretransplant and 1 week posttransplant) and control
subjects (healthy blood donors);
to evaluate longitudinal changes of MDA, TAS, SOD, GPx,
and GR within the first week after KTx and identify
factors associated with these changes;
to investigate the association of MDA/antioxidant parame-
ters with DGF (defined as dialysis requirement within
the first posttransplant week) and their accuracy in
predicting DGF; and
to examine the relationship between any of the oxidative
markers measured during the first week posttransplant
and the 1-year allograft function, evaluated by serum
creatinine (SCr) levels.
RESULTS
Study Cohort
During recruitment, 42 patients were consecutively
enrolled. Two recipients had primary graft failure and were
excluded during the first 2 days. Therefore, the final study
sample included 40 patients. Baseline demographical and
transplant data are shown in Table 1.
Oxidative Stress Markers
We initially compared oxidative markers evaluated in the
40 ESRD patients scheduled for KTx with those of 30 healthy
subjects with similar ages (a control group of blood donors).
Before KTx, the patients presented with significantly increased
mean (SD) MDA levels (0.40 [0.12] vs. 0.26 [0.09] Kmol/L,
PG0.01), TAS (1.79 [0.19] vs. 1.39 [0.53], PG0.001), SOD (1971
[630] vs. 1208 [254] U/g Hb, PG0.001) and GR (63 [12] vs.
52 [7.0] U/L, PG0.001) compared with controls. No significant
differences were detected in GPx.
The evolution of oxidative parameters during the first
posttransplant week is summarized in Table 2. Compared
with before transplant, mean (SD) MDA levels significantly
decreased at first day (0.40 [0.12] vs. 0.36 [0.12] Kmol/L,
P=0.031), and a reduction of approximately 28% was ob-
served on the seventh posttransplant day (0.40 [0.13] to
0.28 [0.13] Kmol/L, PG0.001). Levels of TAS, SOD, GPx, and
GR did not exhibit any significant changes within the first
posttransplant week.
None of the oxidative stress markers differed signifi-
cantly between male and female patients at any time point.
Mean MDA levels were increased in deceased donor re-
cipients at all time points, although the increases were only
statistically significant on second and fourth days. No sig-
nificant differences were found in antioxidant parameters.
Recipient age was positively correlated with MDA
levels at days 4 and 7 (respectively, r=0.46, P=0.004; and
r=0.39, P=0.013). Time on dialysis, donor age, and cold is-
chemia time were not correlated with MDA levels or with
any antioxidant marker. Levels of MDA and SCr, but not of
the antioxidant markers, were positively correlated at most
of time points (data not shown).
TABLE 2. Time-course of oxidative stress biomarkers within the first week after kidney transplantation
Prior-KTx 1st day* 2nd day 4th day 7th day
Mean (SD) (n=40) (n=40) (n=40) (n=40)
MDA (Kmol/L) Overall 0.40 (0.12) 0.36 (0.12) 0.28 (0.10) 0.29 (0.13) 0.28 (0.13)
DGF (n=18) 0.42 (0.12) 0.45 (0.10) 0.33 (0.10) 0.40 (0.13) 0.37 (0.13)
Non-DGF (n=22) 0.39 (0.12) 0.29 (0.09) 0.24 (0.08) 0.23 (0.07) 0.19 (0.05)
TAS (mmol/L) Overall 1.79 (0.19) 1.74 (0.21) 1.68 (0.35) 1.73 (0.37) 1.77 (0.30)
DGF (n=18) 1.80 (0.16) 1.73 (0.24) 1.70 (0.25) 1.82 (0.21) 1.89 (0.24)
Non-DGF (n=22) 1.78 (021) 1.76 (0.19) 1.74 (0.22) 1.75 (0.28) 1.66 (0.32)
SOD (U/g Hb) Overall 1966 (638) 1894 (596) 1984 (578) 1947 (457) 1997 (580)
DGF (n=18) 1842 (559) 1837 (622) 1876 (538) 1928 (439) 2158 (604)
Non-DGF (n=22) 2068 (691) 1943 (584) 2071 (608) 1959 (478) 1944 (413)
GR (U/L) Overall 63 (12) 50 (14) 51 (17) 56 (16) 62 (14)
DGF (n=18) 66 (12) 54 (19) 57 (20) 63 (18) 69 (15)
Non-DGF (n=22) 61 (12) 47 (9) 48 (7) 53 (10) 56 (10)
GPx (U/g Hb) Overall 58 (15) 59 (13) 62 (15) 62 (14) 60 (14)
DGF (n=18) 58 (13) 59 (11) 62 (14) 64 (15) 60 (14)
Non-DGF (n=22) 58 (17) 60 (15) 62 (17) 60 (14) 60 (14)
*1st day=8 to 12 hr after surgery; the values are the mean and standard deviation.
KTx, kidney transplantation; MDA, malondialdehyde; TAS, total antioxidant status; SOD, superoxide dismutase; GR, glutathione reductase; GPx,
glutathione peroxidase; SD, standard deviation.
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Delayed Graft Function and Acute Rejection
Eighteen (45%) and 22 (55%) patients had DGF and
prompt graft function, respectively. The DGF rate was
higher in grafts from deceased donors, but this difference
was not statistically significant (51.7% vs. 27.3%, P=0.286).
In terms of traditional DGF predictors and except for cold
ischemia time, no significant differences were found be-
tween DGF/non-DGF in relation to baseline characteris-
tics and induction therapy (Table 1). The mean age was
significantly higher in patients with DGF (56 [11] vs.
43 [16] yr, P=0.006).
Ten recipients had an acute rejection episode during
inpatient hospitalization for transplantation, and acute re-
jection was more frequently diagnosed in patients with DGF
than in those with prompt function (44% vs. 9%, P=0.025).
DGF and Longitudinal Changes in Oxidative
Stress Markers
Before transplantation, no significant differences were
found between patients with DGF or non-DGF regarding
any of the evaluated oxidative stress markers. After trans-
plantation, mean MDA levels were consistently higher in
DGF patients at all time points, compared with non-
DGF recipients (Table 2). No differences were found
between DGF and non-DGF recipients in relation to anti-
oxidant parameters.
Longitudinal Changes in MDA Levels According
to Graft Function
A linear mixed-effects model was used to analyze the
longitudinal changes in MDA of the 2 groups of patients
(DGF/non-DGF), by controlling for variables found to be
associated with MDA by bivariate analysis (donor status and
recipient age) and confirmed the independent association of
DGF with andMDA levels. Donor status and recipient age lost
their statistical significance and were removed from the final
model. Time measurements of MDA and DGF were the only
independent factors associated with MDA levels (Table 3).
Delayed graft function was significantly associated with MDA
levels: recipients with prompt function presented reduced
average MDA levels at all time points. According to our es-
timation, the first MDA values after transplantation were
0.16 Kmol/L higher in DGF patients. A significant interaction
between time of measurement and DGF confirmed that the
pattern of longitudinal changes in MDA levels depend on
whether the recipient had DGF.
Because DGF occurs more frequently in KTx from
deceased donors, we performed the same analysis consid-
ering only deceased donor transplants, and the results were
similar (see SDC, http://links.lww.com/TP/A919). According
to our estimation and after excluding living donors, the first
MDA levels after KTx were, on average, 0.144 Kmol/L higher
in DGF patients who underwent a deceased-donor transplant.
The effect of DGF on the progression of antioxidant
parameters over time was not statistically significant, even
when we considered only deceased-donors transplants.
Prognosis of DGF by Oxidative Stress Markers
(ROC Analysis)
Receiver-operating characteristic (ROC) analyses were
performed to assess the potential of oxidative markers to
predict DGF. Only MDA levels predicted the need for dial-
ysis within the first week. The MDA levels on day 1 repre-
sented an optimal predictor for the early diagnosis of DGF
(AUC=0.90), as well as the changes in MDA levels between
preoperative and first posttransplant day (AUC=0.84) (Fig. 1).
The diagnostic performance of MDA on day 1 was better
than diagnostic performance of SCr (AUC=0.73) and similar
to that of cystatin C (CystC, AUC=0.91), which is considered
a marker with greater sensitivity for the detection of im-
paired renal function. The reduction ratio in MDA levels
between pretransplant and day 1 resulted in an AUC of 0.84
for identifying DGF, which was better than the reduc-
tion ratio of SCr on the same day (AUC=0.69). In analyzing
TABLE 3. Results of the final linear mixed model for dependent variable MDA levels (n = 194 observations derived from
40 patients)
Estimate P 95% CI
Intercept 0.368 G0.001 0.318 0.418
Graft function
DGF=0 (immediate graft function) Y0.170 G0.001 Y0.238 Y0.102
DGF=1 (with DGF - reference) 0 V V V
Time
Time 0 (pretransplant) 0.053 0.089 Y0.008 0.115
Time 1 (1st day) 0.079 0.012 0.018 0.141
Time 2 (2nd day) Y0.034 0.279 Y0.095 0.028
Time 3 (4th day) 0.030 0.363 Y0.036 0.097
Time 4 (7th day- reference) 0 V V V
Time*DGF
Time 0*DGF=0 0.134 0.002 0.050 0.217
Time 1*DGF=0 0.013 0.257 Y0.070 0.097
Time 2*DGF=0 0.077 0.295 Y0.007 0.161
Time 3*DGF=0 0.029 0.039 Y0.058 0.116
Time 4*DGF=0 (reference) 0 V V V
MDA, Malondialdehyde; DGF, delayed graft function.
* 2014 Lippincott Williams & Wilkins Fonseca et al. 1061
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the ROC curve of MDA on day 1, the optimal sensitivity and
specificity occurred at a value of 0.365 Kmol/L (sensitivity,
83%; specificity, 82%; positive and negative predictive value,
82 and 71, respectively).
During the First Year After KTx
Within the first year after KTx, 10 KTx recipients were
rehospitalized, accounting for a total of 19 hospital admis-
sions. The causes of rehospitalization were infection in five
admissions (predominantly urinary tract infections), renal
dysfunction in six, and nonrenal causes in the remaining eight
admissions (suicidal ideation, acute pulmonary edema, and
neutropenia). Records from the acute rejection episodes
throughout the first posttransplant year were reviewed, and
only one patient was rehospitalized at 1 month after KTx with
an acute rejection episode. At 1 year, all of the patients were
alive, but two grafts of DGF recipients were lost.
Predictive Value of MDA Levels on 1-Year
Allograft Function
At 1 year after KTx, the median (IQR) SCr was signifi-
cantly higher in patients with DGF (1.58 [1.20Y2.52] vs. 1.26
[1.05Y1.52] mg/dL, P=0.049) and a correlation with MDA at
day 7 was found (Fig. 2). The prognostic value of early MDA
values on long-term allograft function (1 year after KTx) was
tested using multivariable analysis, including all patients (DGF
and non-DGF). In multivariable linear regression models for
1-year SCr, MDA levels measured on day 7 were indepen-
dent predictors of 1-year graft function after controlling for
established variables that generally affect graft function, in-
cluding acute rejection and rehospitalizations occurring during
the first posttransplant year (Table 4). Levels of MDA before
KTx and on remaining posttransplant days were not significant
predictors of 1-year SCr.
DISCUSSION
In this prospective cohort study, we report the inde-
pendent association of high levels of plasma MDAwith DGF
with poor 1-year allograft function. To the best of our
knowledge, this study is the first to demonstrate this asso-
ciation in KTx recipients.
Oxidative stress is involved in the pathophysiology of
renal injury in I/R (1, 2, 19). As in other clinical conditions, if
the kidney scavenging capacity is insufficient for an excess of
ROS production, such an oxidative imbalance might trigger an
inflammatory response within the transplanted organ, leading
to tissue damage and graft dysfunction (2, 13, 20). Because of
the composition of renal lipids, which predominantly comprise
long-chain, polyunsaturated fatty acids, lipid peroxidation rep-
resents one of themost widespread hypothesized causes of ROS-
mediated cell injury (21). Despite the controversy of whether
lipid peroxidation is the cause or an epiphenomenon of in-
jury, the fact is that increased lipid peroxidation is observed
in I/R injury. Moreover, MDA is the principal product of
polyunsaturated fatty acid peroxidation, reflecting the I/R
stress of grafts (5, 22). In our study, recipients who developed
DGF presented increased MDA levels during the first week
after KTx, which seem to reflect the postischemic tissue
damage of DGF kidneys. Compared with pretransplant,
these patients presented higher MDA levels at 8 to 12 hr after
KTx, in contrast to recipients with prompt graft function
whose MDA levels continuously decreased throughout the
TABLE 4. Significant predictors of serum creatinine at 1 year after kidney transplantation
Regression coefficient P 95% CI
Serum creatinine at 1-year posttransplantation (ln)
Time on dialysis (ng/mL) 0.048 G0.001 0.024Y0.072
MDA measured on day-7 (Kmol/L) 1.338 0.003 0.475Y2.201
Rehospitalizations (yes vs. no) 0.361 0.007 0.107Y0.615
Results are given by multiple linear regression (a stepwise method) after including donor status, recipient and donor age, pretransplant time on dialysis,
rehospitalizations and acute rejection episodes throughout the first year; serum creatinine (ln) at 1-year after transplant as the dependent variable.
MDA, malondialdehyde.
FIGURE 1. Receiver-operating characteristic curves for
plasma MDA, serum creatinine, and cystatin C levels mea-
suredat the first dayafterKTxandchanges inMDAandserum
creatinine levels from pretransplant to day-1 after KTx for
predicting delayed graft function. The table lists the areas
under the ROC curves of MDA, serum creatinine, and serum
cystatinC for predictingDGF, aswell as the AUCROCofMDA
and serumcreatininechangesbetweenbaseline and first day
after transplant. MDA, malondialdehyde; SCr, serum creati-
nine; Cyst, serum cystatin C;MDA or SCr change (day 1Yday
0), Serum creatinine or MDA reduction rate between pre-
transplant and the first day after transplant (the difference
between MDA or SCr on day 1 and day 0, divided by MDA
or SCr on day 0, multiplied by 100); AUC, area under the
ROC curves.
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week. The independent association of DGF with longitudinal
changes in MDAwas confirmed using a general linear mixed
model approach, which also corroborated that DGF can
model the trajectory of MDA changes after KTx.
Our results not only establish MDA as an early marker
of DGF but also demonstrate its predictive value as early as
8 to 12 hr after KTx in terms of the evolution of graft function
and the need for dialysis during the first week. In regard to
clinical application, a new biomarker should be more accurate
in predicting DGF than the current SCr. After this, ROC
analysis showed thatMDA levels are better suited than SCr for
predicting the need of renal replacement therapy within the
first week after KTx. Similar to serum CystC, MDA levels on
day 1 were highly accurate in predicting DGF and performed
better than SCr. This emphasizes the clinical value of MDA
levels as a diagnostic marker for the prediction of DGF, facil-
itating an earlier diagnosis compared with SCr.
Only a highly effective antioxidant system can coun-
teract the deleterious hydroxyl radicals formed during lipid
peroxidation. A wide range of protective substances, such
as antioxidant enzymes, might potentially elicit a protective
effect by limiting the production of ROS and the damage of
oxidative stress after I/R injury of a kidney graft. Conflicting
results have reported on the activities of antioxidant en-
zymes in KTx patients. Levels of antioxidant enzymes have
been reported to increase (23, 24), decrease (12, 16), or
remain unchanged (25, 26) after KTx. Because of this lack
of consensus, we aimed to examine the changes of antioxi-
dant activity during the early phase of KTx. Compared with
healthy controls, our patients presented with significantly
increased SOD and GR levels before KTx, likely in response to
significant oxidative stress levels in ESRD patients. However,
no significant changes were found after KTx, even when
stratifying by graft function.
The evaluation of TAS has been used as a biologi-
cal marker for monitoring oxidative stress. Measuring TAS
allows for the detection of the overall antioxidant capacity,
including the contribution of as of yet unknown antioxi-
dants and the synergism between them (27). In our study,
TAS levels did not exhibit any significant changes during the
first posttransplant week, even when we stratified the pa-
tients according to DGF. Although oxidative stress expressed
by MDA levels is most significantly pronounced in DGF
patients, our study highlights the observation that during
the first posttransplant week, the overall antioxidant status
and potential protection exerted by the antioxidant enzymes
are not enhanced to counteract the intensified oxidative
stress, specifically in DGF patients.
Immunosuppressive therapy, particularly cyclosporine,
represents an additional potential source of ROS generation
and enhanced renal lipid peroxidation after KTx (15, 28). In
our study, the effect of immunosuppression on plasma MDA
and antioxidant parameters was not assessed, as only one
patient was on a combined therapy with cyclosporine.
In various studies, it has been reported that oxidative
stress occurring in KTx might be implicated in the patho-
physiology of chronic transplant dysfunction (1, 11, 15, 17,
29). Djamali et al. (30) suggested that ROS represents an im-
portant fibrogenic factor in chronic allograft nephropathy
because oxidative stress is increased in the presence of the
interstitial fibrosis and tubular atrophy that generally precedes
chronic allograft failure. In experimental models of chronic
allograft tubular atrophy/interstitial fibrosis, increased intra-
graft MDA levels were detected, reflecting lipid peroxidation
(31). Therefore, we verified the effects ofMDA levels evaluated
within the first week on 1-year posttransplant allograft func-
tion. Together with time on dialysis and rehospitalizations
during the first year, MDA levels at day 7 were the best pre-
dictors of 1-year SCr. Higher MDA levels on day 7 were as-
sociated with worse graft function at 1 year, suggesting that
oxidative damage reflected by increased MDA levels on day 7
will reflect long-term injury.
This study has several strengths. We used a prospective
and longitudinal study design to determine the effects of DGF
on the progression of oxidative markers over time.Most of the
previous oxidative stress studies on KTx were cross-sectional
and included only stable patients. Longitudinal studies are
more helpful in understanding how subtle associations be-
tween factors of interest change over time, and we used this
methodology to consider five measurements of each oxidative
stress marker. Uncertainty remains concerning the determi-
nation of oxidative stress in KTx and the interpretation of the
potential variability. However, our study highlights the im-
portance of studying oxidative stress according to graft func-
tion because DGF can significantly modify the trajectory of
MDA changes. To the best of our knowledge, this is the first
study to demonstrate that MDA levels are strongly associated
with DGF and with poorer 1-year graft function.
Regardless of its several mentioned strengths, this study
has some limitations. This is a single centre study with a rela-
tively small sample size. Despite the encouraging results found,
the accuracy ofMDA levels as a diagnostic marker of renal graft
injury and prognostic value of MDA for DGF after KTx needs
to be assessed in a larger cohort and in other centers and
transplant recipients.
In KTx, numerous diagnostic biomarkers have been
evaluated in the past decade, but, so far, evidence to support
FIGURE 2. Relationship between serum creatinine and
plasma malondialdehyde at day 7 after kidney transplan-
tation (r=0.346, P=0.031). KTx, kidney transplantation; SCr,
serum creatinine.
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their use in routine practice is limited. The discovery of
novel biomarkers can be complex and costly. In this study,
we demonstrated that a novel marker predicted who would
develop DGF with about the same degree of accuracy of serum
CystC and both with a diagnostic performance superior to
serum creatinine. Undoubtedly, CystC displays several good
characteristics that make it a viable biomarker for early de-
tection of DGF. Nonetheless, and particularly during the first
week when high doses of corticosteroids are used, glucocorti-
coid medication can be shortcoming in using serum CystC in
KTx, and it is important to take this into account when
interpreting this serum marker. Thus, a combination of bio-
markers may be more valuable for the diagnosis of DGF and
prognosis of graft function. Because DGF is a critical early
insult to the renal allograft that augments the risk of long-term
graft loss, and it is a complex process with multiple underlying
pathogenic mechanisms and confounding risk factors, it can
be prudent to predict DGF with more than a single biomarker,
at least in some situations. MDA can be a valuable marker as
an alternative or as a complement in the risk prediction, not
only in relation to serum CystC and any other serum/plasma
markers but also regarding urine biomarkers, like neutrophil
gelatinase-associated lipocalin, that cannot be measured if a
urine sample cannot be taken, particularly during transient
anuria that commonly occurs after KTx.
In conclusion, intensified oxidative stress persists during
the early phase of transplant, particularly in DGF recipients. The
antioxidant enzymes did not counterbalance the overload of
ROS by a compensatory increase in their activities. The present
study showed that MDA is a novel and a reliable biomarker for
the prediction of early and long-term graft damage.
SUBJECTS AND METHODS
Study Design and Patient Population
Consecutive patients with end-stage renal disease (ESRD), undergoing
living or deceased KTx at the Nephrology and Kidney Transplantation De-
partment of the Centro Hospitalar do Porto between December 2010 and
May 2011 were prospectively enrolled. Patients younger than 18 years or who
requiredmultiorgan transplants were not included. After transplant, recipients
with primary graft failure related to surgical causes were excluded. The insti-
tutional review board of Centro Hospitalar do Porto approved the study. Each
participant provided informed consent before enrollment.
Data Collection
At time of transplantation, several demographical and clinical parame-
ters were collected. During the first posttransplant year, the rehospital-
izations of KTx recipients were registered, as well as the length of the
hospital stays and outcomes (functioning allograft or graft failure).
Sampling and Laboratory
Blood samples for determining oxidative stress parameters were collected
as follows: 3 to 6 hr before transplant surgery (pretransplant); on the fol-
lowing morning, approximately 8 to 12 hr after graft reperfusion (day 1);
and then at second (day 2), fourth (day 4), and seventh day (day 7) after
transplant, for a total of five samples per patient. Blood samples were taken
by conventional procedures and immediately centrifuged. All samples were
aliquoted and frozen within 1 hr after collection and stored at Y80oˆ¤C until
further assay.
Measurements of SCr were performed by Jaffe´ method (Roche Diagnostics),
and CystC was measured with a particle enhanced immunonephelometric
method (Siemens Diagnostics) at the same time points as oxidative markers.
Plasma levels ofMDAweremeasured using a commercial high-performance
liquid chromatography kit (Chromsystems). superoxide dismutase levels were
measured in erythrocytes according to a protocol previously described by
Beauchamp and Fridovich (32) using the RANSOD kit; GR, GPx, and TAS
levels were measured in plasma/serum using a Randox Laboratories kit.
Definition of Variables
Delayed graft function was defined by the need for dialysis during the
first week. ‘‘Prompt’’ function (non-DGF) was considered if no dialysis was
required during the first posttransplantation week.
Graft function at 1 year was evaluated by the average of the two SCr levels
measured at 1 year posttransplant. Two grafts were lost at the seventh and
eighth months, and the last SCr presented by these patients before the re-
start of dialysis was considered as being the 1-year SCr.
Statistics
Distributions of continuous variables were analyzed, and Kolmogorov-
Smirnov tests were performed to assess their deviation from Normal distri-
bution. Quantitative variables were summarized as the mean and standard
deviation (SD), or as median and 25th and 75th quartiles (interquartile range
[IQR]) for variables exhibiting skewed distributions. Categorical variables
were reported as percentages.
Statistical analysis was performed in four steps. First, a cross-sectional
bivariate analysis was performed to compare groups and to study the as-
sociation between oxidative stress markers and demographic/clinical vari-
ables (t test). Correlations were assessed using Pearson correlation.
Second, a linear mixed-effects model was used to study the association of
DGF with serial changes of each oxidative marker, controlling for variables
associated by bivariate analysis. The interaction between DGF and the time-
course measurement of oxidative markers were included in the model, as
such a significant interaction would suggest that DGF affects the levels and
trajectory of each marker.
Third, ROC analysis was performed to estimate the sensitivity and
specificity of MDA levels (as well as SCr and CystC) to predict DGF. The
optimal cutoff points were determined by maximizing the sum of sensitivity
and specificity.
Fourth, multivariable stepwise linear regression was performed to assess
the independent association of MDA levels with SCr at 1 year posttransplan-
tation, including variables that generally predict graft function (donor status,
recipient and donor age, pretransplant time on dialysis, rehospitalization, and
acute rejection episodes throughout the first year). Linear regression models
used log-transformed 1-year SCr levels as the dependent variable. To avoid
collinearity, each time point of MDA was included separately in the dif-
ferent models.
Statistical analyses were performed using SPSS version 21.0, and a sig-
nificance level of 0.05 was considered significant.
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